Search

Displaying results 3111 - 3120 of 6198 in total
  1. Drug

    ATB-346

    go.drugbank.com/drugs/DB15377
    Investigational

    ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).

  2. Drug

    Vecabrutinib

    go.drugbank.com/drugs/DB16657
    Investigational

    Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).

  3. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive

  4. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … [A275482, L56120] Linerixibat functions by interrupting the enterohepatic circulation of these bile acids, thereby reducing their systemic concentration.[A275482]

  5. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.

  6. Drug

    Thioproperazine

    go.drugbank.com/drugs/DB01622
    Approved

    Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually ...

  7. Drug

    Aminosalicylic acid

    go.drugbank.com/drugs/DB00233
    ApprovedInvestigational

    An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.

  8. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.

  9. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529].

  10. Target

    B-cell receptor CD22

    go.drugbank.com/bio_entities/BE0000183
    TargetHumans

    Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). … If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366)

    Synonyms: BL-CAM